Latanoprost Eg

Latanoprost, the active ingredient in Latanoprost Eg, is a Prostaglandin F2α analog presented as an ophthalmic solution for ocular (topical) use. It lowers intraocular pressure and is used to treat open-angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage conditions that involve elevated intraocular pressure.

Open‑angle glaucoma: reduces intraocular pressure, helping to preserve visual field and prevent optic nerve damage. Ocular hypertension: lowers intraocular pressure to reduce the risk of progression to glaucoma.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Conjunctival hyperemia (eye redness) - Increased eyelash growth - Darkening of iris pigmentation - Eye irritation or foreign‑body sensation - Blurred vision - Mild eye pain

Serious or Rare Side Effects: - Ocular inflammation (uveitis) - Severe allergic reaction (angio‑edema) - Corneal edema or macular edema - Significant changes in visual acuity - Persistent eye pain - Acute angle‑closure glaucoma (rare)

Before initiating therapy, clinicians should consider several safety aspects.

Monitor intraocular pressure regularly: ensure therapeutic effect and detect over‑reduction. Assess for ocular infections: avoid use if active infection is present. Evaluate history of uveitis: prostaglandin analogs may exacerbate inflammation. Use caution in patients with asthma: systemic prostaglandin effects can trigger bronchospasm. Avoid contact lens wear during treatment: lenses may absorb the drug and cause irritation. Store at ambient temperature: keep the bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops: may increase risk of ocular side effects. - Use with non‑steroidal anti‑inflammatory eye drops: can diminish Latanoprost's IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive intraocular pressure reduction may require monitoring. - Alpha‑agonist eye drops: combined therapy may enhance pressure‑lowering but increase irritation. - Systemic carbonic anhydrase inhibitors: monitor for excessive IOP reduction.